In April 2026 the FDA removed BPC-157 along with a number of other peptides, TB-500 among them from the Section 503A Category 2 list that had restricted compounding, and a Pharmacy Compounding Advisory Committee meeting on 2324 July 2026 is due to consider them further
While the medication has demonstrated substantial weight loss in clinical trials, it is important to understand that tirzepatide is not specifically a "fat-burning" agent in the traditional sense, but rather works through appetite suppression and metabolic regulation
it's figuring out which pieces of it actually change something for you
GLP Winner Founder and CEO Yesterday the FDA proposed removing GLP-1s from the 503B bulk list, and I spoke to Kurt Lunkwitz from ProRx to talk about changes to GLP-1 compounding
Learn which natural ingredients can suppress appetite and find if these natural appetite suppressants help with weight loss
doi: 10.3390/toxins9040132 105 KimSSRuizVECarrollJDMossSF